medmix Annual report 2023
Our key figures
Our revenue increased by 2.0% (1.1% organically). We delivered profitability of 19.1% adjusted EBITDA margin and a free cash flow of CHF 3.4 million.
Share of revenue by market segment
2023
Share of revenue by market segment
2022
Key figures
|
millions of CHF |
|
2023 |
|
% of revenue |
|
+/–% change |
|
2022 |
|
% of revenue |
|
Revenue |
|
486.6 |
|
100.0% |
|
2.0% |
|
477.1 |
|
100.0% |
|
Organic revenue growth 1) |
|
|
|
|
|
1.1% |
|
|
|
|
|
Gross profit |
|
157.6 |
|
32.4% |
|
–10.1% |
|
175.4 |
|
36.8% |
|
Operating income (EBIT) |
|
16.0 |
|
3.3% |
|
–18.5% |
|
19.6 |
|
4.1% |
|
EBITDA |
|
74.4 |
|
15.3% |
|
5.2% |
|
70.7 |
|
14.8% |
|
Adjusted EBITDA |
|
93.1 |
|
19.1% |
|
–11.7% |
|
105.4 |
|
22.1% |
|
Net income attributable to shareholders of medmix Ltd |
|
0.3 |
|
0.1% |
|
–97.5% |
|
11.6 |
|
2.4% |
|
Adjusted net income |
|
36.9 |
|
7.6% |
|
–37.2% |
|
58.7 |
|
12.3% |
|
Adjusted diluted earnings per share, attributable to a shareholder of medmix Ltd (in CHF) |
|
0.90 |
|
|
|
–37.3% |
|
1.43 |
|
|
|
Free cash flow (FCF) |
|
3.4 |
|
|
|
–67.5% |
|
10.3 |
|
|
|
Adjusted operating net cash flow (adjusted ONCF) |
|
40.8 |
|
|
|
9.3% |
|
37.3 |
|
|
|
Capital expenditure, net (capex, net) |
|
66.3 |
|
|
|
77.6% |
|
37.3 |
|
|
|
Net debt as of December 31 |
|
219.0 |
|
|
|
39.8% |
|
156.7 |
|
|
|
Net debt adjusted EBITDA ratio as of December 31 |
|
2.35 |
|
|
|
58.2% |
|
1.49 |
|
|
|
Employees (number of full-time equivalents) as of December 31 |
|
2’658 |
|
|
|
28.6% |
|
2’067 |
|
|
1) Adjusted for acquisition and currency effects.
Our KEY Figures
revenue in 2023
adjusted EBITDA margin
free cash flow generated in 2023
Stock market information
|
|
|
2023 |
|
2022 |
|
|
|
|
Registered share (in CHF) |
|
|
|
|
|
|
|
|
– high |
|
26.38 |
|
47.00 |
|
|
|
|
– low |
|
16.45 |
|
15.70 |
|
|
|
|
– year-end |
|
19.00 |
|
17.60 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Market capitalization as of December 31 |
|
|
|
|
|
|
|
|
– number of shares issued |
|
41’262’370 |
|
41’262’370 |
|
|
|
|
– in millions of CHF |
|
784 |
|
726 |
|
|
|
|
– in percentage of equity |
|
168% |
|
144% |
|
|
|
|
|
|
|
|
|
|
|
|
|
P/E ratio as of December 31 |
|
2’674.3x |
|
62.4x |
|
|
|
|
Dividend yield as of December 31 |
|
2.6% |
|
2.8% |
|
|
|
Data per share
|
CHF |
|
2023 |
|
2022 |
|
|
|
|
Net income attributable to a shareholder of medmix Ltd |
|
0.01 |
|
0.28 |
|
|
|
|
Equity attributable to a shareholder of medmix Ltd |
|
11.30 |
|
12.20 |
|
|
|
|
Ordinary dividend |
|
0.50 1) |
|
0.50 |
|
|
|
|
Payout ratio |
|
7’038% |
|
177% |
|
|
|
|
Average number of shares outstanding |
|
40’868’426 |
|
40’957’744 |
|
|
|
1) Proposal to the Annual General Meeting.
Shareholder structure as per December 31, 2023
|
Number of shares |
|
Number of shareholders |
|
Shareholding |
|
1–100 |
|
2’883 |
|
0.4% |
|
101–1’000 |
|
4’187 |
|
3.9% |
|
1’001–10’000 |
|
783 |
|
5.1% |
|
10’001–100’000 |
|
92 |
|
6.2% |
|
More than 100’000 |
|
22 |
|
52.6% |
|
Total registered shareholders and shares (excluding treasury shares medmix Ltd) |
|
7’967 |
|
68.2% |
Shareholder structure as per December 31, 2022
|
Number of shares |
|
Number of shareholders |
|
Shareholding |
|
1–100 |
|
3’127 |
|
0.4% |
|
101–1’000 |
|
4’677 |
|
4.2% |
|
1’001–10’000 |
|
743 |
|
4.9% |
|
10’001–100’000 |
|
91 |
|
5.8% |
|
More than 100’000 |
|
23 |
|
55.1% |
|
Total registered shareholders and shares (excluding treasury shares medmix Ltd) |
|
8’661 |
|
70.4% |
Global reach, local presence
